Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm by Site — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site

Other

Neoplasm by Site

CI-CAN-00000003Explore in graph →

Non-malignant20,485 active trials253 approved drugs3,567 evidence items

NCIt: C3263
MeSH: D009371

Overview
Statistics
Survival
Genomics477
Variants & evidence3567
Drugs398
Trials92566
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,037)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 26, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 4,026–4,037 of 4,037 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Genomic landscape of locally advanced rectal adenocarcinoma: Comparison between before and after neoadjuvant chemoradiation and effects of genetic biomarkers on clinical outcomes and tumor response.
· Cancer Med · 2023 · PMID 37260182 · validated civic_curation pubmed
Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
· JCI Insight · 2018 · PMID 29467336 · validated civic_curation pubmed
High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.
· J Transl Med · 2024 · PMID 39639373 · validated civic_curation pubmed
Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
· Mol Oncol · 2020 · PMID 32502294 · validated civic_curation pubmed
TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses.
· Clin Exp Med · 2025 · PMID 41249701 · validated civic_curation pubmed
Identification of fusions with potential clinical significance in melanoma.
· Mod Pathol · 2022 · PMID 35871080 · validated civic_curation pubmed
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
· J Natl Cancer Inst · 2017 · PMID 28040692 · validated

Showing 4,026–4,037 of 4,037 publications

← Previous
1
…
161
162
Next →

civic_curation

Rucaparib or Physician's Choice in Metastatic Prostate Cancer.

· N Engl J Med · 2023 · PMID 36795891 · validated civic_curation pubmed

Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma.

· JCO Precis Oncol · 2022 · PMID 35977348 · validated civic_curation pubmed

Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.

· Acta Neuropathol Commun · 2022 · PMID 36104744 · validated civic_curation pubmed

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration.

· NPJ Precis Oncol · 2023 · PMID 36964191 · validated civic_curation pubmed

Case Report: triple therapy with pembrolizumab, ipilimumab, and lenvatinib in mitotane- and radiation-refractory, cortisol-secreting stage IV adrenocortical carcinoma: a genomically guided approach.

· Front Immunol · 2026 · PMID 42158873 · validated civic_curation pubmed